Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Global X MSCI Argentina ETF (ARGT) vs Ginkgo Bioworks Holdings Inc (DNA) Price & Performance

Global X MSCI Argentina ETF
Ginkgo Bioworks Holdings Inc

Price performance

Price movement over the last 24 hours

Key statistics

Global X MSCI Argentina ETF vs Ginkgo Bioworks Holdings Inc — how do they compare? Global X MSCI Argentina ETF trades at $95.07, while Ginkgo Bioworks Holdings Inc trades at $9 (market cap $593.80M). The key difference: Global X MSCI Argentina ETF is trading nearer its 52-week high, Ginkgo Bioworks Holdings Inc nearer its low. Which is the better fit depends on your goals.

ARGTDNA
Sector
Broad Market / FactorHealth
52-Week High
$102.94$16.14
52-Week Low
$67.55$5.48
Market Cap
$593.80M
Enterprise Value
$631.04M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Global X MSCI Argentina ETF

ARGT (Global X MSCI Argentina ETF) trades at $95.07, up 3.08% with a neutral technical signal. The ETF shows bullish moving averages but mixed oscillators, with support at $92 and resistance at $93. Recent positive sentiment stems from Argentina's economic reforms under the Milei Administration, with Seeking Alpha upgrading the rating to buy citing 28% upside potential based on valuation re-rating opportunities.

The outlook appears constructive given Argentina's improving macroeconomic backdrop, though concentration risk in MercadoLibre and ongoing economic transition pose challenges. Wall Street sentiment has turned positive with institutional accumulation noted, but investors should monitor fiscal stabilization progress and inflation trends for sustained momentum.

Ginkgo Bioworks Holdings Inc

DNA trades at $9.09, down 6.58% on the day, reflecting ongoing investor caution. The technical outlook is bullish based on moving averages, with key support at $9 and resistance at $10. Fundamentally, the company reported a net loss of $312.76M on $170.16M revenue in 2025, with a negative net margin of -201.05%. Recent news highlights include Ginkgo Bioworks' Q1 2026 results and its strategic pivot to autonomous laboratories following the divestiture of its biosecurity business.

The outlook remains challenging due to persistent losses and high cash burn, though the technical setup suggests potential for a near-term bounce. Investment opportunity hinges on successful execution of the new lab strategy driving future profitability. Key risks include continued negative earnings, competitive pressures in biotech, and reliance on the unproven autonomous lab model for growth.

Returns comparison

Trailing returns across standard periods

About Global X MSCI Argentina ETF

ARGT seeks to provide investment results that correspond to the performance of the MSCI All Argentina 25/50 Index. It offers targeted exposure to some of the largest and most liquid companies operating in Argentina.

Read more on ARGT

About Ginkgo Bioworks Holdings Inc

Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.

Read more on DNA